Sarcoidosis and Crohn’s disease are systemic granulomatous disorders affecting the lung and the intestine, respectively, with variable involvement of other organs and are seldom associated. While anti-TNFα is a recognized treatment of Crohn’s disease, its usage is discussed in sarcoidosis. A 42-year-old man presented with an 11-year-long history of Crohn’s disease; upon discovery of an abnormal chest CT scan the diagnosis of multivisceral sarcoidosis was made and, later, a treatment with an anti-TNFα agent, infliximab, was started, because of worsening Crohn’s disease recurrences. CT scan demonstrated net regression of pulmonary opacities and hepatosplenic lesions. Pathologies obtained from the intestinal tract and the bronchi of the patient were, respectively, characteristic of Crohn’s disease and sarcoidosis leading to the diagnosis of both diseases. We report a rare case of steroid resistant Crohn’s disease associated with multivisceral sarcoidosis, treated successfully by an anti-TNFα agent, infliximab. 1. Introduction Both sarcoidosis and Crohn’s disease are relapsing chronic inflammatory disorders characterized by the formation of granulomas; they share some organ locations, cytokine pathways, and genetic background. The association of both diseases has rarely been reported. If anti-TNFα is a recognized treatment of Crohn’s disease, its role in sarcoidosis remains discussed. We report the association of both diseases in a single patient and the beneficial effect of anti-TNFα on both diseases. 2. Case Report A 42-year-old man presented with a 3-month history of respiratory symptoms combining mild dyspnea, cough, asthenia, and weight loss. His past medical history included a 6-pack-year smoking habit and an 11-year-long history of Crohn’s disease, treated with oral steroids (prednisolone 20?mg/day) ever since. Over time, repeated biopsies showing ulceration and transmural inflammatory lesions of the ileum, the colon, and the rectum including submucosal aggregates of lymphocytes and plasmocytes and, once, rectal epithelioid granulomas were always consistent with the diagnosis. Physical exam showed no abnormalities. Peripheral blood lymphocyte count was decreased (890/μL including 374 CD4 lymphocytes/μL, i.e., 42%); serum angiotensin converting-enzyme level was elevated (118?U/L). CT scan was markedly abnormal (Figures 1(a), 1(b), and 1(c)) showing enlarged bilateral hilar and mediastinal lymph nodes, a left apical irregular nodule, bilateral perihilar infiltrates, upper lobe micronodules, proximal bronchial thickening, and hepatic and splenic
References
[1]
M. Esmadi, D. S. Ahmad, B. Odum, et al., “Sarcoidosis: an extremely rare cause of granulomatous enterocolitis,” Journal of Gastrointestinal and Liver Diseases, vol. 21, no. 4, pp. 423–425, 2012.
[2]
P. Camus and T. V. Colby, “The lung in inflammatory bowel disease,” European Respiratory Journal, vol. 15, no. 1, pp. 5–10, 2000.
[3]
E. Pain-Prado, A. Rais, F. Madhi, C. Orzechowski, B. Dubern, and R. Epaud, “Pulmonary and hepatic nodular lesions precede the diagnosis of Crohn's disease in an 8-year-old girl: a case study and review of the literature,” Acta Paediatrica, vol. 101, no. 2, pp. e86–e89, 2012.
[4]
L. Kallel, M. Fekih, I. Ben Ghorbel, et al., “Un cas exceptionnel de sarcoidose systemique suivie par une maladie de Crohn: une association fortuite ou lien etiopathogenique?” La Presse Médicale, vol. 39, no. 1, pp. 148–150, 2010.
[5]
H. Y. Reynolds, “Sarcoidosis: impact of other illnesses on the presentation and management of multi-organ disease,” Lung, vol. 180, no. 5, pp. 281–299, 2002.
[6]
J. H. Park and A. I. Levinson, “Granulomatous-lymphocytic interstitial lung disease (GLILD) in common variable immunodeficiency (CVID),” Clinical Immunology, vol. 134, no. 2, pp. 97–103, 2010.
[7]
M. Drent, K. Mansour, and C. Linssen, “Bronchoalveolar lavage in sarcoidosis,” Seminars in Respiratory and Critical Care Medicine, vol. 28, no. 5, pp. 486–495, 2007.
[8]
C. H. van Moorsel and D. C. Christiani, “Genetic susceptibility to sarcoidosis, a chronic inflammatory disorder,” American Journal of Respiratory and Critical Care Medicine, vol. 186, no. 9, pp. 816–818, 2012.
[9]
J. T. Tigno-Aranjuez and D. W. Abbott, “Ubiquitination and phosphorylation in the regulation of NOD2 signaling and NOD2-mediated disease,” Biochimica et Biophysica Acta, vol. 1823, no. 11, pp. 2022–2028, 2012.
[10]
A. Franke, A. Fischer, M. Nothnagel et al., “Genome-wide association analysis in sarcoidosis and Crohn's disease unravels a common susceptibility locus on 10p12.2,” Gastroenterology, vol. 135, no. 4, pp. 1207–1215, 2008.
[11]
A. Fischer, B. Schmid, D. Ellinghaus, et al., “A novel sarcoidosis risk locus for Europeans on chromosome 11q13.1,” American Journal of Respiratory and Critical Care Medicine, vol. 186, no. 9, pp. 877–885, 2012.
[12]
J. F. Mornex, C. Leroux, T. Greenland, and D. Ecochard, “From granuloma to fibrosis in interstitial lung diseases: molecular and cellular interactions,” European Respiratory Journal, vol. 7, no. 4, pp. 779–785, 1994.
[13]
C. Abraham and J. H. Cho, “Inflammatory bowel disease,” New England Journal of Medicine, vol. 361, no. 21, pp. 2066–2078, 2009.
[14]
L. Peyrin-Biroulet, P. Deltenre, N. de Suray, J. Branche, W. J. Sandborn, and J. Colombel, “Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of Placebo-controlled trials,” Clinical Gastroenterology and Hepatology, vol. 6, no. 6, pp. 644–653, 2008.
[15]
R. P. Baughman, E. E. Lower, and M. Drent, “Inhibitors of tumor necrosis factor (TNF) in sarcoidosis: who, what, and how to use them,” Sarcoidosis Vasculitis and Diffuse Lung Diseases, vol. 25, no. 2, pp. 76–89, 2008.
[16]
H. Takahashi, K. Kaneta, M. Honma et al., “Sarcoidosis during infliximab therapy for Crohn's disease,” Journal of Dermatology, vol. 37, no. 5, pp. 471–474, 2010.
[17]
D. Tong, N. Manolios, G. Howe, and D. Spencer, “New onset sarcoid-like granulomatosis developing during anti-TNF therapy: an under-recognised complication,” Internal Medicine Journal, vol. 42, no. 1, pp. 89–94, 2012.
[18]
L. Javot, S. Tala, J. Scala-Bertola et al., “Sarco?dosis and anti-TNF: a paradoxical class effect? Analysis of the French pharmacovigilance system database and literature review,” Therapie, vol. 66, no. 2, pp. 149–154, 2011.
[19]
C. A. Parisinos, C. W. Lees, W. A. H. Wallace, and J. Satsangi, “Sarcoidosis complicating treatment with natalizumab for Crohn's disease,” Thorax, vol. 66, no. 12, pp. 1109–1110, 2011.